REFERENCES
1. Chidambaranathan-reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res 2021;149:1-61.
2. Cucchetti A, Trevisani F, Cescon M, et al. Italian Liver Cancer (ITA. LI.CA) Group. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. J Hepatol 2012;56:1089-96.
3. Renzulli M, Golfieri R. Bologna Liver Oncology Group (BLOG). Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver disease. J Gastroenterol Hepatol 2016;31:69-80.
4. Liver cancer [homepage on the Internet]. The global cancer observatory cancer fact sheets (2018). Available from: http://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf [Last accessed on 11 May 2022].
5. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003;38:136-49.
6. Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
7. Forner A, Real MI, Varela M, Bruix J. Transarterial chemoembolization for patients with hepatocellular carcinoma. Hepatol Res 2007;37 Suppl 2:S230-7.
8. Okuda K, Ohnishi K, Kimura K, et al. Incidence of portal vein thrombosis in liver cirrhosis. Gastroenterology 1985;89:279-86.
9. Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 2015;7:2009-19.
10. Tovoli F, Renzulli M, Negrini G, et al. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. Eur Radiol 2018;28:3611-20.
11. Tovoli F, Ielasi L, Casadei-Gardini A, et al. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol 2019;71:1175-83.
12. Zaky S, Makhlouf NA, Abdel Malek MO, et al. Multidisciplinary decision making in the management of hepatocellular carcinoma: a hospital-based study. Turk J Gastroenterol 2015;26:498-505.
13. Varela M, Reig M, de la Mata M, et al. Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers. Med Clin (Barc) 2010;134:569-76.
14. Giannini EG, Moscatelli A, Pellegatta G, et al. Italian Liver Cancer (ITA. LI.CA) Group., Italian Liver Cancer ITA LI CA Group. Application of the intermediate-stage subclassification to patients with untreated hepatocellular carcinoma. Am J Gastroenterol 2016;111:70-7.
15. Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev 2019;72:28-36.
16. Maas M, Beets-Tan R, Gaubert JY, et al. Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice. Insights Imaging 2020;11:83.
17. Karaosmanoglu AD, Onur MR, Uysal A, Akata D, Ozmen MN, Karcaaltincaba M. Tumor in the veins: an abdominal perspective with an emphasis on CT and MR imaging. Insights Imaging 2020;11:52.
18. Vasuri F, Golfieri R, Fiorentino M, et al. OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation. Virchows Arch 2011;459:141-6.
19. Renzulli M, Brandi N, Argalia G, et al. Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions. Radiol Med 2022;127:129-44.
20. Renzulli M, Peta G, Vasuri F, et al. Standardization of conventional chemoembolization for hepatocellular carcinoma. Ann Hepatol 2021;22:100278.
21. Idilman I, Peynircioğlu B, Cil BE, et al. Transarterial chemoembolization for treatment of hepatocellular carcinoma: a single center experience. Turk J Gastroenterol 2013;24:141-7.
22. Terzi E, Terenzi L, Venerandi L, et al. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series. Dig Dis 2014;32:711-6.
23. Cucchetti A, Trevisani F, Cappelli A, et al. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Dig Liver Dis 2016;48:798-805.
24. Wu X, Chapiro J, Malhotra A, Kothary N. Comparison of drug-eluting embolics versus conventional transarterial chemoembolization for the treatment of patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis. J Vasc Interv Radiol 2021;32:2-12.e1.
25. Kudo M, Han KH, Ye SL, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: asia-pacific primary liver cancer expert consensus statements. Liver Cancer 2020;9:245-60.
26. Cavallo JJ, Forman HP. The economic impact of the COVID-19 pandemic on radiology practices. Radiology 2020;296:E141-4.
27. Marasco G, Nardone OM, Maida M, Boskoski I, Pastorelli L, Scaldaferri F. Italian Association of Young Gastroenterologist and Endoscopist (AGGEI). Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: a European survey. Dig Liver Dis 2020;52:1396-402.
30. Procopet B, Berzigotti A. Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterol Rep (Oxf) 2017;5:79-89.
31. Renzulli M, Dajti E, Ierardi AM, et al. Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients. Eur J Radiol 2022;147:110010.
32. Mosconi C, Gramenzi A, Biselli M, et al. Survival and tolerability of transarterial chemoembolization in greater versus less than 70 Years of age patients with unresectable hepatocellular carcinoma: a propensity score analysis. Cardiovasc Intervent Radiol 2020;43:1015-24.
33. Iwazawa J, Ohue S, Hashimoto N, Mitani T. Comparison of the number of image acquisitions and procedural time required for transarterial chemoembolization of hepatocellular carcinoma with and without tumor-feeder detection software. Radiol Res Pract 2013;2013:580839.
34. Granito A, Facciorusso A, Sacco R, et al. TRANS-TACE: prognostic role of the transient hypertransaminasemia after conventional chemoembolization for hepatocellular carcinoma. J Pers Med 2021;11:1041.
35. Gui CH, Baey S, D'cruz RT, Shelat VG. Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - a meta-analysis. Eur J Surg Oncol 2020;46:763-71.
36. Vogl TJ, Riegelbauer LJ, Oppermann E, et al. Early dynamic changes in circulating tumor cells and prognostic relevance following interventional radiological treatments in patients with hepatocellular carcinoma. PLoS One 2021;16:e0246527.
37. Chen S, Peng Z, Zhang Y, et al. Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: abandon or repeat? Radiology 2021;298:680-92.
38. Campos JT, Sirlin CB, Choi JY. Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: the atlas. Insights Imaging 2012;3:451-74.
39. Golfieri R, Garzillo G, Ascanio S, Renzulli M. Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines. Dig Dis 2014;32:696-704.
40. Park HJ, Jang HY, Kim SY, et al. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound. J Hepatol 2020;72:718-24.
